全文获取类型
收费全文 | 31192篇 |
免费 | 1802篇 |
国内免费 | 151篇 |
专业分类
耳鼻咽喉 | 292篇 |
儿科学 | 419篇 |
妇产科学 | 343篇 |
基础医学 | 4169篇 |
口腔科学 | 978篇 |
临床医学 | 2016篇 |
内科学 | 7405篇 |
皮肤病学 | 845篇 |
神经病学 | 2181篇 |
特种医学 | 1250篇 |
外科学 | 5533篇 |
综合类 | 146篇 |
一般理论 | 1篇 |
预防医学 | 965篇 |
眼科学 | 641篇 |
药学 | 2428篇 |
中国医学 | 43篇 |
肿瘤学 | 3490篇 |
出版年
2021年 | 474篇 |
2020年 | 324篇 |
2019年 | 398篇 |
2018年 | 515篇 |
2017年 | 475篇 |
2016年 | 504篇 |
2015年 | 545篇 |
2014年 | 711篇 |
2013年 | 902篇 |
2012年 | 1334篇 |
2011年 | 1469篇 |
2010年 | 851篇 |
2009年 | 780篇 |
2008年 | 1305篇 |
2007年 | 1305篇 |
2006年 | 1338篇 |
2005年 | 1423篇 |
2004年 | 1321篇 |
2003年 | 1337篇 |
2002年 | 1259篇 |
2001年 | 1282篇 |
2000年 | 1316篇 |
1999年 | 1179篇 |
1998年 | 360篇 |
1997年 | 312篇 |
1996年 | 272篇 |
1995年 | 275篇 |
1994年 | 243篇 |
1993年 | 234篇 |
1992年 | 818篇 |
1991年 | 723篇 |
1990年 | 732篇 |
1989年 | 697篇 |
1988年 | 710篇 |
1987年 | 622篇 |
1986年 | 613篇 |
1985年 | 597篇 |
1984年 | 391篇 |
1983年 | 323篇 |
1982年 | 148篇 |
1980年 | 132篇 |
1979年 | 318篇 |
1978年 | 203篇 |
1977年 | 151篇 |
1975年 | 149篇 |
1974年 | 213篇 |
1973年 | 151篇 |
1972年 | 165篇 |
1971年 | 147篇 |
1969年 | 131篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
2.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
3.
4.
5.
6.
7.
8.
Higuchi Takashi Sugisawa Norihiko Yamamoto Jun Oshiro Hiromichi Han Qinghong Yamamoto Norio Hayashi Katsuhiro Kimura Hiroaki Miwa Shinji Igarashi Kentaro Tan Yuying Kuchipudi Shreya Bouvet Michael Singh Shree Ram Tsuchiya Hiroyuki Hoffman Robert M. 《Cancer chemotherapy and pharmacology》2020,85(2):285-291
Cancer Chemotherapy and Pharmacology - Cancers are methionine (MET) and methylation addicted, causing them to be highly sensitive to MET restriction. The present study determined the efficacy of... 相似文献
9.
10.
Shogo Yamamoto Yutaka Midorikawa Genta Nagae Kenji Tatsuno Hiroki Ueda Mitsuhiko Moriyama Tadatoshi Takayama Hiroyuki Aburatani 《Cancer science》2020,111(2):601-609
Multiple hepatocellular carcinoma (HCC) is divided into two categories: intrahepatic metastasis (IM), which is a true relapse of HCC, and multicentric origin (MO), which is a second primary tumor. Clinical diagnosis of multiple HCC is usually made based on tumor location and/or time to recurrence; however, it is often difficult to distinguish the two types of multiple HCC. Using 41 matched pairs of multiple HCC specimens, we confirmed the accuracy of clinical diagnoses using exome sequence data and investigated the importance of discriminating the type of multiple HCC. Genomic analysis revealed that 18 (43.9%) patients diagnosed as having genomic IM had common mutations in a pair of HCC tumors with the main tumor of these patients being more progressive compared to those with genomic MO. The accuracy of clinical diagnosis based on lobe (Definition 1) and segment (Definition 2) were 68.3% and 78.0%, respectively. Intriguingly, recurrence ≥2 years after initial surgery for 3 patients was IM. The survival of patients with clinical IM was significantly shorter than for those with clinical MO based on both Definition 1 (P = 0.045) and Definition 2 (P = 0.043). However, mean survival was not different between the patients with genomic IM and those with MO (P = 0.364). Taken together, genomic analysis elucidated that liver cancer may spread more extensively and more slowly than previously thought. In addition, distinguishing multiple HCC as IM or MC may have provided biological information but was not of clinical importance with respect to patient prognosis. 相似文献